Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone hexacetonide
Drug ID BADD_D02274
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D00985
MeSH ID C005900
PubChem ID 21826
TTD Drug ID Not Available
NDC Product Code 52128-177; 46439-8728; 59137-570
UNII I7GT1U99Y9
Synonyms triamcinolone hexacetonide | 9-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-(3,3-dimethylbutyrate) | Aristospan
Chemical Information
Molecular Formula C30H41FO7
CAS Registry Number 5611-51-8
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)COC(=O)CC(C)(C)C)C)O)F)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle disorder15.05.03.014---
Muscular weakness15.05.06.001; 17.05.03.005--
Myocardial rupture02.04.02.002; 12.01.11.002---
Myopathy15.05.05.001---
Nausea07.01.07.001--
Neuritis17.09.03.001---
Neuropathic arthropathy05.07.04.011; 14.07.04.011; 15.01.04.008; 17.09.03.008---
Neuropathy peripheral17.09.03.003---
Nitrogen balance negative13.13.01.010---
Oedema08.01.07.006; 14.05.06.010---
Osteonecrosis15.02.04.007; 24.04.05.004--
Osteoporosis14.04.04.002; 15.02.03.002--
Pancreatitis07.18.01.001--
Papilloedema06.09.02.002; 17.07.02.004; 24.03.07.001--
Paraesthesia17.02.06.005; 23.03.03.094--
Paraparesis17.01.04.006---
Paraplegia17.01.04.007---
Pathological fracture12.04.02.006; 15.08.02.008; 16.32.03.007---
Peptic ulcer07.04.07.001---
Personality change17.02.05.019; 19.05.01.006--
Petechiae01.01.03.002; 23.06.01.003; 24.07.06.004---
Pulmonary oedema02.05.02.003; 22.01.03.003--
Rash23.03.13.001---
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014---
Seizure17.12.03.001--
Sensory disturbance17.02.07.006---
Skin atrophy23.01.05.001--
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.003---
Skin hyperpigmentation23.05.01.003--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages